Skip to content

Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis

Evaluation of the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031430
Enrollment
Unknown
Registered
2020-03-31
Start date
2020-03-20
Completion date
Unknown
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Conventional treatment regimen + MSC treatment
Control group:Conventional treatment regimen

Sponsors

The Fifth Medical Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Male or female patients aged form 18 to 80 years; 2) Willing to sign informed consent; 3) Confirmed cases who meet "Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol" revised by the National Health Commission of the Peoples Republic of China. 4) High-resolution CT indicates interstitial injures in the lungs (honeycomb shadows or grid shadows).

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) High-resolution CT before the onset of the disease suggests the presence of interstitial injures in lungs; 3) Acute interstitial lung injures caused by other reasons (within two weeks); 4) Invasive ventilator assisted ventilation; 5) Multiple organ dysfunction syndrome.

Design outcomes

Primary

MeasureTime frame
Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;

Countries

China

Contacts

Public ContactFu-Sheng Wang

The Fifth Medical Center of PLA General Hospital

fswang302@163.com+86 010-66933332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026